http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100925559-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-538 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-38 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100925559-B1 |
| titleOfInvention | DDR and collagen binding inhibitors containing actinomycin D as an active ingredient |
| abstract | The present invention relates to DDR and collagen binding inhibitors using actinomycin D as an active ingredient, and more particularly, to the use of actinomycin D in a method for treating a disease caused by excessive activity of DDR protein. will be. The extracellular domain of DDR has the property of binding to collagen protein, which is a ligand of DDR, and actinomycin D has an excellent activity of inhibiting these bindings, resulting in cancer, liver cirrhosis, rheumatism or arteriosclerosis caused by the excess activity of DDR protein. It can be usefully used for prevention and treatment.n n n n DDR, Insect Cells, Actinomycin D, Tyrosine Kinase, Collagen |
| priorityDate | 2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 640.